Analysts at Catapult Wealth are positive on sleep treatment company ResMed and think it could be an ASX 200 share to buy. Catapult Wealth's analysts have been pleased with ResMed's performance in ...

In the latest quarter, 5 analysts provided ratings for ResMed RMD, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...